Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
General Medication Fact Sheet for Retevmo
| Field | Information |
|---|---|
| Medication Name | Retevmo |
| Generic Name | Selpercatinib |
| Boxed/Label Warning | Retevmo can cause serious side effects, including interstitial lung disease/pneumonitis, liver problems, high blood pressure, heart rhythm changes (QT prolongation), and increased risk of bleeding. It can also cause tumor lysis syndrome, severe hypersensitivity reactions, impaired wound healing, and thyroid dysfunction. Females of reproductive potential should use effective contraception during treatment and for 2 weeks after the last dose. Males with female partners of reproductive potential should use effective contraception during treatment and for 1 week after the last dose. |
| Purpose | Tyrosine kinase inhibitor used to treat certain types of cancers with RET (rearranged during transfection) alterations. |
| Mechanism of Action | Selectively inhibits RET kinase activity, leading to decreased cell proliferation and increased apoptosis in RET-altered cancer cells. |
| Dosage Forms | Oral capsules |
| Available Strengths | 40 mg, 80 mg |
| Dosage Frequency | Twice daily |
| Common Side Effects | Dry mouth, diarrhea, fatigue, edema, rash, abdominal pain, constipation, nausea, headache, cough, vomiting, dyspnea, decreased appetite, QT prolongation |
| Serious Side Effects | Interstitial lung disease/pneumonitis, hepatotoxicity, hypertension, QT prolongation, hemorrhagic events, hypersensitivity, tumor lysis syndrome, impaired wound healing, hypothyroidism |
| Drug Interactions | Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin), strong CYP3A4 inducers (e.g., rifampin, phenytoin), CYP3A4 substrates, P-gp substrates |
| Important Notes | Take Retevmo on an empty stomach, at least 2 hours before or 1 hour after a meal. Do not open or crush capsules. Monitor for signs and symptoms of interstitial lung disease/pneumonitis, hepatotoxicity, hypertension, and QT prolongation. Inform your doctor of any medications, supplements, and pre-existing medical conditions before starting treatment. |
| Storage | Store at room temperature away from moisture and light. |
| Missed Dose | If a dose is missed by more than 6 hours, skip the missed dose and take the next dose at its regularly scheduled time. Do not take two doses at the same time to make up for a missed dose. |
| Alternatives | Cabozantinib (Cabometyx), Vandetanib (Caprelsa), Other chemotherapy regimens (specific to cancer type and RET alteration) |
Retevmo Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Cabozantinib (Cabometyx) | Tyrosine kinase inhibitor | Inhibits multiple receptor tyrosine kinases including RET, VEGFR, MET, AXL, and FLT3. Used for medullary thyroid cancer and other cancers. |
| Vandetanib (Caprelsa) | Tyrosine kinase inhibitor | Inhibits RET, VEGFR, and EGFR. Used for medullary thyroid cancer. |
| Chemotherapy Regimens | Varies depending on regimen | Traditional cytotoxic agents used to kill cancer cells. Used when targeted therapies are not effective or appropriate. Specific regimens depend on cancer type. |
Retevmo Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Dry mouth | Interstitial lung disease/pneumonitis |
| Diarrhea | Hepatotoxicity (liver damage) |
| Fatigue | Hypertension (high blood pressure) |
| Edema (swelling) | QT Prolongation (heart rhythm changes) |
| Rash | Hemorrhagic events (bleeding) |
| Abdominal pain | Hypersensitivity reactions |
| Constipation | Tumor lysis syndrome |
| Nausea | Impaired wound healing |
| Headache | Hypothyroidism |
| Cough | None |
| Vomiting | None |
| Dyspnea | None |
| Decreased appetite | None |
Retevmo Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| Non-Small Cell Lung Cancer (NSCLC) with RET fusion | 120 mg twice daily (for patients ≥50 kg); 160 mg/m² twice daily (for patients <50 kg) | Same as starting dose | Take on an empty stomach (at least 2 hours before or 1 hour after a meal). Dosage adjustments may be necessary for adverse reactions. |
| Medullary Thyroid Cancer (MTC) with RET mutation | 120 mg twice daily (for patients ≥50 kg); 160 mg/m² twice daily (for patients <50 kg) | Same as starting dose | Take on an empty stomach (at least 2 hours before or 1 hour after a meal). Dosage adjustments may be necessary for adverse reactions. |
| Other RET-altered solid tumors | 120 mg twice daily (for patients ≥50 kg); 160 mg/m² twice daily (for patients <50 kg) | Same as starting dose | Take on an empty stomach (at least 2 hours before or 1 hour after a meal). Dosage adjustments may be necessary for adverse reactions. |
Retevmo Price With And Without Insurance
| Purchase Context | Estimated Price |
|---|---|
| With Insurance | $60 |
| Without Insurance (U.S.) | $24,500 |
| From CPS | $6,105 |
